课题基金 / 基金详情

Dissection of microRNA-21s role in non-small cell lung cancer

Dissection of microRNA-21s role in non-small cell lung cancer
剖析 microRNA-21 在非小细胞肺癌中的作用
批准号:
8454731
负责人:
Mark Edward Hatley
金额:
$16.85万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-01 至 2016-08-31

项目摘要

项目成果

Mark Edward Hatley的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract This proposal described a tailored basic research training program for the transition from post-doctoral fellow to independent investigator. The principle investigator has a Ph.D. in Cell Regulation, completed a structured residency training program in Pediatrics and is near the completion of clinical fellowship training in Pediatric Hematology/Oncology. The proposal described herein will foster a command on microRNA-21's (miR-21) role in the progression of non-small cell lung cancer (NSCLC). In this regard, Dr. Eric Olson the chairman of Molecular Biology at the University of Texas Southwestern and a world's authority on mouse models of microRNA and disease will serve as an ideal mentor. He has trained numerous post-doctoral fellows in the past and has sponsored previous and current physician scientists. To enhance the training, the program will enlist the expertise of Dr. John Minna, Professor of Internal Medicine and Pharmacology an expert in the molecular basis of lung cancer, Dr. Luis Parada, Chairman of Developmental Biology a premier cancer biologist and mouse geneticist, and Dr. George Lister, Chairman of Pediatrics. Furthermore, this advisory committee will not only provide regular constructive criticism of data, hypotheses, and proposed experiments but invaluable advice regarding career development as an independent and productive physician scientist. It is also expected that the members of the advisory committee will be invaluable in offering their expertise and unique reagents to foster the research plan. The research will focus on elucidating the molecular mechanisms underlying the role of miR-21 in the progression of non-small cell lung cancer. Recent work in the Olson laboratory has established that miR-21 expression modifies the progression of NSCLC in a mouse model of NSCLC. The proposed experiments will build on this observation utilizing transgenic mouse models and tumor cell lines from these models to determine the importance of miR-21 in lung cancer and the mechanism through which miR-21 contributes to non-small cell lung cancer development. The specific aims include: 1) Determine the role of miR-21 in development NSCLC in vivo, 2) Define the mechanisms responsible for miR-21 promotion of NSCLC pathogenesis, 3) Explore miR-21 inhibition as therapy for NSCLC. This will be the first detailed functional analysis of miR-21 in vivo using a mouse model of cancer and gain-of-function and loss-of-function miR-21 transgenic mice. The combination of the Molecular Biology Department and the NCI-Cancer Center at UT Southwestern provides an ideal setting for training physician-scientist by incorporating expertise from diverse resources into customized programs. This environment will provide the ideal interdisciplinary setting not only to conduct the proposed experiments but to develop as an independent clinician scientist from which an academic career can be constructed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma
Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma
Mediators Of Arrested Differentiation In Pediatric Rhabdomyosarcoma
Defining the non-myogenic origins of pediatric rhabdomyosarcoma
国内基金
海外基金
湘西黄牛源片形吸虫抗丙硫咪唑关键蛋白基因表达microRNA的筛选、鉴定及其调控模式研究
  • 批准号:
    2026JJ80492
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    李中波
  • 依托单位:
枳实通降颗粒通过LncRNA TUG1/microRNA-9-5p/MAPK信号轴调控巨噬细胞代谢重编程防治POI及相关性肺损伤的机制研究
长链非编码RNA PURPL通过microRNA-342/IGF1R轴对恶性黑色素瘤生物学行为的调控研究
  • 批准号:
    2025JJ80880
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    张璋
  • 依托单位:
有氧运动经microRNA预防肥胖相关性肾损伤的机制研究
  • 批准号:
    JCZRQN202500941
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: